Hamps Bio Limited

The next results date for Hamps Bio is 14 November 2025.

Hamps Bio has shown steady revenue growth, with net sales increasing from 5.58 Cr in Mar'23 to 6.67 Cr in Mar'25, but profitability metrics have declined, including a drop in profit after tax from 0.50 Cr to 0.30 Cr. Total assets and liabilities have significantly increased, indicating higher leverage, while cash flow from operating activities has remained stagnant.

The next results date for Hamps Bio is 13 November 2025.

As of 01-October, Hamps Bio Limited's stock price is declining at 20.35, down 4.15%, and has significantly underperformed its sector and the broader market, with a year-to-date drop of 50.77%. Despite a rise in delivery volume, there are no clear factors explaining the stock's recent poor performance.

As of 26-Sep, Hamps Bio Limited's stock price is Rs 22.32, down 4.98% and has declined 22.55% over the past week, significantly underperforming the benchmark Sensex. The stock is trading below key moving averages with reduced investor participation, indicating specific challenges for the company.

As of 24-Sep, Hamps Bio Limited's stock price is Rs 24.72, down 5.0% and has declined 14.23% over the past week, significantly underperforming compared to the Sensex. Year-to-date, the stock has fallen 40.20%, indicating negative investor sentiment relative to market trends.

As of 23-Sep, Hamps Bio Limited's stock is priced at Rs 26.02, down 4.97% and underperforming significantly compared to the Sensex, which has only declined by 0.34% over the past week. The stock has shown erratic trading patterns and a year-to-date decline of 37.05%, reflecting negative investor sentiment.

As of 22-Sep, Hamps Bio Limited's stock is priced at 27.38, down 5.0%, and has significantly underperformed year-to-date with a decline of 33.76%. Despite increased investor participation, the stock's erratic trading and negative performance contrast sharply with the broader market's gains.

As of 12-Sep, Hamps Bio Limited's stock price is at 28.82, down 1.97% and has declined 30.28% year-to-date, significantly underperforming the Sensex. Despite a recent increase in delivery volume, the stock continues to struggle with negative sentiment and volatility.

As of 11-Sep, Hamps Bio Limited's stock is priced at 29.40, down 2.0%, and has underperformed its sector and the broader market significantly, with a year-to-date decline of 28.87%. The stock shows erratic trading patterns and decreased investor participation, indicating ongoing struggles.

As of September 9, 2025, Hamps Bio is considered very expensive and overvalued with a PE ratio of 13.07 and an EV to EBITDA of 15.94, significantly lagging behind peers like Sun Pharma and Cipla, while also experiencing a year-to-date return of -27.42% compared to the Sensex's 3.79% gain.

As of September 8, 2025, Hamps Bio is considered expensive and overvalued with a PE ratio of 13.07, despite a recent stock performance improvement, as it has a year-to-date return of -27.42%, significantly lower than peers like Sun Pharma and Divi's Lab.

As of 05-Sep, Hamps Bio Limited's stock price is at 60.00, having increased by 1.97% over the last week, with a total return of 14.74%. Despite recent gains, the stock has a year-to-date decline of 27.42%, indicating volatility and challenges in maintaining investor confidence.

As of 04-Sep, Hamps Bio Limited's stock price is at 58.84, having increased by 1.99% over the last six days, with a total return of 12.53%. Despite outperforming its sector and the benchmark recently, a decline in delivery volume raises concerns about the sustainability of this upward trend.

Hamps Bio recently announced a 1:1 bonus issue, granting shareholders an additional share for each share held, with an ex-date and record date of September 8, 2025.

As of 03-Sep, Hamps Bio Limited's stock price is Rs 57.69, up 2.0% and has gained 10.33% over the past week, outperforming the Sensex. However, a decline in delivery volume raises concerns about sustained investor interest despite the stock's strong upward momentum.

As of 02-Sep, Hamps Bio Limited's stock price is at 56.56, having increased by 1.98% over the last four days and outperforming the Sensex in the short term. However, a significant drop in investor participation raises concerns about the sustainability of this upward trend.

As of 01-Sep, Hamps Bio Limited's stock price is 55.46, having increased by 1.99% over the last three days and outperforming the Sensex. Despite recent gains, the stock has a year-to-date decline of 32.91%, indicating volatility and long-term performance concerns.

As of 29-Aug, Hamps Bio Limited's stock price is at 54.38, having increased by 1.97% recently and outperforming its sector. Despite a year-to-date decline of 34.22%, the stock shows signs of recovery with a 4% return over the past week, indicating rising investor interest.